Supervalu Inc. (SVU) Drops 7.48% on January 14

Equities Staff  |

Supervalu Inc. (SVU) was one of the Russell 2000's biggest losers for Thursday January 14 as the stock slid 7.48% to $4.70, a loss of $-0.38 per share. Starting at an opening price of $4.92 a share, the stock traded between $4.46 and $4.97 over the course of the trading day. Volume was 12.26 million shares over 38,047 trades, against an average daily volume of 3.65 million shares and a total float of 265.92 million.

The losses send Supervalu Inc. down to a market cap of $1.25 billion. In the last year, Supervalu Inc. has traded between $12.00 and $4.95, and its 50-day SMA is currently $6.61 and 200-day SMA is $8.12.

The stock has a P/E Ratio of 7.6.

SUPERVALU Inc are wholesale distributors to independent retail customers across the United States through its Independent Business segment and the Retail Food segment. Substantially all of the Company's operations are domestic.

Supervalu Inc. is based out of Eden Prairie, MN and has some 38,500 employees. Its CEO is Eric Claus.

For a complete fundamental analysis analysis of Supervalu Inc., check out’s Stock Valuation Analysis report for SVU. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:



Symbol Last Price Change % Change










What Is Petrolithium?

MGX Minerals explains the advantages of petrolithium and how they are helping to solve future problems today.

Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.